Key Transaction Details

Investment Structure: Concord Biotech Limited has entered into an agreement to invest in M/s FSGE Renewable Power Private Limited by acquiring 27.38% of its equity share capital.

Investment Amount: The company proposes to invest ₹6.3 crore in one or more tranches for subscription of equity share capital.

Consideration Type: Cash consideration.

Completion Timeline: The equity shares against the current investment will be allotted within 60 days from the agreement date.

Regulatory Approvals: No governmental or regulatory approvals are required for this acquisition of shares.

Target Entity Details

Corporate Identity Number: U42202GJ2023PTC143958

Date of Incorporation: August 19, 2023

Business Activity: Captive power generation through renewable energy. FSGE is a Special Purpose Vehicle incorporated for developing a captive power generation facility for Concord Biotech Limited.

Current Status: The company is in the process of setting up a hybrid renewable energy plant and has not commenced commercial operations.

Capital Structure (as of June 15, 2026):

  • Authorized Share Capital: ₹1,00,000 divided into 10,000 equity shares of ₹10 each
  • Paid-up Share Capital: ₹1,00,000 divided into 10,000 equity shares of ₹10 each

Project Specifications

Project Type: Wind-Solar Hybrid Power Project

Location: Gujarat, for Limbasi Facility of Concord Biotech Limited

Capacity:

  • Wind Capacity: Approximately 6.3 MW AC
  • Solar Capacity: Approximately 6.3 MWp DC

Transaction Rationale and Impact

The investment aligns with the company's commitment to sustainability and focused efforts to address environmental challenges. The transition to renewable energy sources will:

  • Reduce the company's carbon footprint
  • Contribute to global efforts to combat climate change
  • Offer long-term financial benefits through reduction in energy costs
  • Enhance operational efficiency
  • Ensure compliance with evolving environmental regulations
  • Support sustainable growth

Regulatory Classification

Upon 27.38% equity share acquisition, FSGE will become an associate of Concord Biotech Limited, making this investment fall under the purview of Related Party Transaction. The investment and subscription of shares will be conducted at arm's length basis. None of the promoter/promoter group/group companies have any interest in the entity being acquired.

Historical Context

This disclosure is in continuation to the company's intimation dated November 13, 2025.